Fw: e-Newsletter for Tuesday, July 31, 2012

[Guest guest]

From: "HIVandHepatitis.com" <newsletter@...>Date: Tue, 31 Jul 2012 15:37:46 -0400 (EDT)<nelsonvergel@...>Reply newsletter@...Subject: e-Newsletter for Tuesday, July 31, 2012Having trouble viewing this email?Click here e-Newsletter for Tuesday, July 31, 2012 Complete Coverage of the XIX International AIDS Conference (AIDS 2012)(Articles by Topic) HIV/AIDS Cobicistat Matches Ritonavir as Booster for Atazanavir The novel boosting agent cobicistat works as well as ritonavir (Norvir) as a pharmacoenhancer, or booster, for the first-line protease inhibitor atazanavir (Reyataz) at 48 weeks, according to a report presented last week at the 19th International AIDS Conference in Washington, DC. Full Article Once-daily Elvitegravir Suppresses HIV as well as Raltegravir at 96 weeks The investigational HIV integrase inhibitor elvitegravir taken once-daily continued to perform as well as twice-daily raltegravir (Isentress) at 96 weeks for treatment-experienced people with extensive drug resistance, according to data presented last week at the 19th International AIDS Conference (AIDS 2012) in Washington, DC. Full Article No HIV Found in Stem Cell Transplant Recipients Who Remain on ART Two men who underwent bone marrow transplants for lymphoma using milder chemotherapy that allowed them to remain on antiretroviral therapy (ART) show no traces of HIV, researchers reportedlast week at the XIX International AIDS Conference (AIDS 2012) in Washington, DC. While not repeating the " Berlin Patient " HIV cure, these cases offer further insight into possible strategies for eradicating the virus. Full Article Berlin Patient Brown Launches Foundation for HIV Cure Ray Brown -- better know as the " Berlin Patient, " the first person known to be cured of HIV -- launched a new foundation to raise funds for HIV cure research at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. He took the opportunity to announce that he is still free of HIV. Full Article Syringe Exchange Expansion in U.S. Would be Cost-saving According to a mathematical analysis presented at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC, providing clean syringes to reduce HIV transmission among Americans who inject drugs is considerably less expensive than treating the new cases of HIV that would occur in the absence of this intervention. Full Article Other Health News Novel PzMA Tuberculosis Combo Shows Potent Activity in Short-term Trial A triple-combination regimen consisting of the experimental tuberculosis (TB) drug PA-824, the established TB drug pyrazinamide, and the widely used antibiotic moxifloxacin -- dubbed PaMZ -- showed potent bactericidal activity in a randomized 14-day study presented last week at the XIX International AIDS Conference (AIDS 2012) in Washington, DC, and published simultaneously in the July 23, 2012 issue of The Lancet. Full Article Forward emailThis email was sent to nelsonvergel@... by newsletter@... | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114